Tamar Tadmor, Guy Melamed, Hilel Alapi, Sivan Gazit, Tal Patalon, Lior Rokach
{"title":"Intake of Proton Pump Inhibitors is Associated with a Shorter Time To First Treatment in early-stage Chronic Lymphocytic Leukemia.","authors":"Tamar Tadmor, Guy Melamed, Hilel Alapi, Sivan Gazit, Tal Patalon, Lior Rokach","doi":"10.1159/000541453","DOIUrl":null,"url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide(1). The use of PPI has become a common practice, and are overprescribed for all patients with cancer including patients with hematological malignancies. In the current study, we aimed to explore retrospectively the effect of PPI, on time to first treatment (TTFT) in a large cohort of patients with Chronic lymphocytic leukemia who were under watch and wait approach. Our cohort included 3,474 patients with CLL who are treatment-naïve, and the median follow-up was 1745 days (602-3700). 1061 patients (30.5%) received a PPI agent, for a minimum of 3 months during the watch-and-wait period. The intake of PPI was found to be associated with a shorter TTFT: among PPI users, the ten years treatment free ratio is 79.2%, while among non PPI users it is 90.6%. In conclusion, routine use of PPI in CLL patients may negative impact their clinical course. Biology of this primary observation require further investigation.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541453","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide(1). The use of PPI has become a common practice, and are overprescribed for all patients with cancer including patients with hematological malignancies. In the current study, we aimed to explore retrospectively the effect of PPI, on time to first treatment (TTFT) in a large cohort of patients with Chronic lymphocytic leukemia who were under watch and wait approach. Our cohort included 3,474 patients with CLL who are treatment-naïve, and the median follow-up was 1745 days (602-3700). 1061 patients (30.5%) received a PPI agent, for a minimum of 3 months during the watch-and-wait period. The intake of PPI was found to be associated with a shorter TTFT: among PPI users, the ten years treatment free ratio is 79.2%, while among non PPI users it is 90.6%. In conclusion, routine use of PPI in CLL patients may negative impact their clinical course. Biology of this primary observation require further investigation.
期刊介绍:
''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.